^
    Back
    Association details:
    Biomarker:CD8 expression
    Cancer:Renal Cell Carcinoma
    Drug:Opdivo (nivolumab) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO-GU 2020
    Title:

    Integrative genomic profiling of RCC treated with second-line nivolumab.

    Published date:
    02/14/2020
    Excerpt:
    Integrative genomic sequencing analysis of ccRCC tumors in Nivolumab treated patients revealed CD8 expression as a putative biomarker.